| 中文名 | Zaurategrast乙酯 |
|---|---|
| 英文名 | ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate |
| 中文别名 |
(S)-3-(4 - ((2,7-萘啶-1-基)氨基)苯基)-2 - ((2-溴-3-氧代螺〔3.5
(S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-((2-溴-3-氧代螺〔3.5〕壬-1-烯-1-基基)氨基)丙酸甲酯 |
| 英文别名 |
UCB1184197)
Zaurateast ethyl ester ethyl-(2S)-2-(2-bromo-3-oxospiro[3,5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate L-Phenylalanine, N-(2-bromo-3-oxospironon-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-, ethyl ester Zaurateast ethyl ester (Synonyms: CDP323 Zaurateast Ethyl Ester (CDP323 (S)-ethyl-3-(4-(2,7-naphthyridin-1-ylamino)phenyl)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)propanoate L-Phenylalanine,N-(2-bromo-3-oxospiro(3.5)non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-,ethyl ester ethyl 2(S)-(2-bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate (S)-ethyl 3-(4-(2,7-naphthyridin-1-ylaMino)phenyl)-2-(2-broMo-3-oxospironon-1-en-1-ylaMino)propanoate |
| 描述 | Zaurategrast ethyl ester (CDP323) 是 CT7758 的乙酯前药,是 α4β1/α4β7 整联蛋白拮抗剂,可用于治疗炎症和自身免疫疾病。 |
|---|---|
| 相关类别 | |
| 靶点 |
α4β1/α4β7 integrin[1] |
| 体外研究 | Zaurategrast乙酯(CDP323)是CT7758的乙酯前药,在增加传质方面显示出一些改进[1]。 |
| 参考文献 |
| 分子式 | C28H29BrN4O3 |
|---|---|
| 分子量 | 549.46 |
| 精确质量 | 548.14200 |
| PSA | 93.21000 |
| LogP | 6.04080 |
| 储存条件 | 2-8℃ |
|
~91%
455264-30-9 |
| 文献:CELLTECH R and D LIMITED Patent: WO2004/7428 A1, 2004 ; Location in patent: Page 56 ; |
|
~%
455264-30-9 |
| 文献:Schuele, Arnaud; Ates, Celal; Palacio, Magali; Stofferis, Jimmy; Delatinne, Jean-Pierre; Martin, Bruno; Lloyd, Steven Organic Process Research and Development, 2010 , vol. 14, # 4 p. 1008 - 1014 |
| 上游产品 1 | |
|---|---|
| 下游产品 1 | |